Compare TH & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | LBRX |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.5M | 563.2M |
| IPO Year | N/A | 2025 |
| Metric | TH | LBRX |
|---|---|---|
| Price | $6.97 | $22.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.00 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 311.7K | 239.5K |
| Earning Date | 11-06-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $314,546,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.00 | $13.36 |
| 52 Week High | $10.28 | $24.46 |
| Indicator | TH | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 56.45 |
| Support Level | $7.28 | $21.82 |
| Resistance Level | $7.76 | $24.46 |
| Average True Range (ATR) | 0.25 | 1.90 |
| MACD | -0.12 | 0.17 |
| Stochastic Oscillator | 0.00 | 67.52 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. Its operating segment includes HFS-South and HFS-Midwest; Government; TCPL Keystone and others. It generates a majority of its revenue from the Government segment which consists of specialty rental and vertically integrated hospitality services revenue from customers with Government contracts located in Texas.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.